Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative …
…, DR Head, JM Rowe, SJ Forman… - Blood, The Journal …, 2000 - ashpublications.org
The associations of cytogenetics with complete remission (CR) rates, overall survival (OS),
and outcomes after CR were studied in 609 previously untreated AML patients younger than …
and outcomes after CR were studied in 609 previously untreated AML patients younger than …
[HTML][HTML] Regression of glioblastoma after chimeric antigen receptor T-cell therapy
…, M Chen, J Portnow, SJ Forman… - … England Journal of …, 2016 - Mass Medical Soc
<p id="p001">A patient with recurrent multifocal glioblastoma received chimeric antigen
receptor (CAR)–engineered T cells targeting the tumor-associated antigen interleukin-13 …
receptor (CAR)–engineered T cells targeting the tumor-associated antigen interleukin-13 …
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
…, T Maniar, B Huber, D Nagorsen, SJ Forman… - The Lancet …, 2015 - thelancet.com
Background Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia
have an unfavourable prognosis. Blinatumomab is a bispecific T-cell engager antibody …
have an unfavourable prognosis. Blinatumomab is a bispecific T-cell engager antibody …
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
…, SE James, A Raubitschek, SJ Forman… - Blood, The Journal …, 2008 - ashpublications.org
Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is
a promising approach to cancer therapy that has not previously been explored for the …
a promising approach to cancer therapy that has not previously been explored for the …
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
…, JA Ressler, J Portnow, M D'Apuzzo, SJ Forman… - Clinical cancer …, 2015 - AACR
Purpose: A first-in-human pilot safety and feasibility trial evaluating chimeric antigen
receptor (CAR)–engineered, autologous primary human CD8 + cytotoxic T lymphocytes (CTL) …
receptor (CAR)–engineered, autologous primary human CD8 + cytotoxic T lymphocytes (CTL) …
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate …
…, CL Sawyers, DA Arber, ML Slovak, SJ Forman - Blood, 2003 - ashpublications.org
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel,
Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous …
Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous …
[HTML][HTML] Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T …
…, D DiGiusto, M Kalos, JR Ostberg, SJ Forman - Biology of blood and …, 2010 - Elsevier
Immunotherapeutic ablation of lymphoma is a conceptually attractive treatment strategy that
is the subject of intense translational research. Cytotoxic T lymphocytes (CTLs) that are …
is the subject of intense translational research. Cytotoxic T lymphocytes (CTLs) that are …
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
…, LE Budde, A Raubitschek, SJ Forman… - Blood, The Journal …, 2012 - ashpublications.org
Cellular immune responses have the potential to elicit dramatic and sustained clinical remissions
in lymphoma patients. Recent clinical trial data demonstrate that modification of T cells …
in lymphoma patients. Recent clinical trial data demonstrate that modification of T cells …
CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T …
…, S Olivares, N Gonzalez, DD Smith, SJ Forman… - Cancer research, 2006 - AACR
Chimeric antigen receptors (CAR) combine an antigen-binding domain with a CD3-ζ signaling
motif to redirect T-cell specificity to clinically important targets. First-generation CAR, such …
motif to redirect T-cell specificity to clinically important targets. First-generation CAR, such …
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
…, M Sherman, JR Ostberg, SJ Forman… - Blood, The Journal …, 2011 - ashpublications.org
An unmet need in cell engineering is the availability of a single transgene encoded,
functionally inert, human polypeptide that can serve multiple purposes, including ex vivo cell …
functionally inert, human polypeptide that can serve multiple purposes, including ex vivo cell …